U.S. testing new rapid response vaccine-delivery platform

Health officials in the United States are currently testing a new vaccine-delivery platform developed by the Halifax, Nova Scotia-based Immunovaccine, Inc.

The DepoVax vaccine-delivery platform is intended for use in rapid response to a bioterrorist event involving either civilians or the military, according to TheChroncicleHerald.ca.

"Our platform seems to enhance the effectiveness of some vaccines that could be used to counter bioterrorism events," Marc Mansour, Immunovaccine's chief science officer, said, TheChronicleHerald.ca reports. "The challenge for military or civil authorities is to have a particular vaccine take effect as quickly as possible."

Mansour said that DepoVax has the ability to generate an immune response rapidly.

The U.S. National Institute of Allergy and Infectious Diseases plans to include the vaccine-delivery platform in additional testing slated to begin this spring. DepoVax will be one of several vaccines and vaccine boosters to be included in the round of non-human primate tests.

Immunovaccine recently announced that DepoVax could serve to advance the development of next generation vaccines that could be used against the deadliest of biological agents, including anthrax and Marburg virus.

"This collaboration is consistent with Immunovaccine's strategy for leveraging DepoVax to enhance the immunogenicity of even the best vaccine antigen candidates in as little as a single dose," John Trizzino, the chief executive officer at Immunovaccine, said, TheChronicleHerald.ca reports.